idarubicin has been researched along with Abnormalities, Autosome in 33 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (21.21) | 18.2507 |
| 2000's | 12 (36.36) | 29.6817 |
| 2010's | 14 (42.42) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arellano, M; Carlisle, JW | 1 |
| Audisio, E; D'Ardia, S; Di Bello, C; Di Celle, PF; Frairia, C; Inghirami, G; Marmont, F; Messa, E; Pich, A; Riera, L; Sismondi, F; Toppino, D; Vitolo, U | 1 |
| Abraham, R; Barkoh, BA; Luthra, R; Medeiros, LJ; Mehrotra, M; Mishra, BM; Patel, KP; Ravandi, F; Sargent, RL | 1 |
| Jang, JH; Jung, CW; Jung, HA; Kim, K; Kim, SJ; Maeng, CH; Park, S | 1 |
| Borthakur, G; Brandt, M; Cortes, J; Daver, N; Garcia-Manero, G; Jabbour, E; Kadia, T; Kantarjian, H; Patel, K; Pemmaraju, N; Pierce, S; Ravandi, F; Wang, X | 1 |
| Dou, MH; Hu, C; Huang, J; Jin, J; Li, Y; Lou, YJ; Luo, YW; Ma, LY; Mao, LP; Mei, C; Niu, LM; Ren, YL; Tong, HY; Wang, JH; Wei, JY; Xie, LL; Xu, GX; Ye, L; Ye, XN; Yu, WJ; Zhou, XP | 1 |
| Kim, SY; Lee, MH | 1 |
| Beltrão, EI; Benicio, MT; Bezerra, MA; Bezerra, MF; Coelho-Silva, JL; Lucena-Araujo, AR; Machado, CG; Nascimento, JC; Rego, EM; Rocha, CR | 1 |
| Jones, RL; Kulkarni, S; Mehta, J; Morgan, G; Potter, M; Powles, R; Saso, R; Singhal, S; Sirohi, B; Smith, K; Swansbury, GJ; Treleaven, J | 1 |
| Afzal, M; Khan, F; Sherwani, AF | 1 |
| Adeyinka, A; Kuriakose, P; Zuberi, L | 1 |
| Betts, DR; Bourquin, JP; Bradtke, J; Creutzig, U; Dworzak, MN; Haas, OA; Reinhardt, D; Sander, A; Stary, J; von Neuhoff, C; Zemanova, Z; Zimmermann, M | 1 |
| Fong, C; Tong, M | 1 |
| Celentano, M; Criscuolo, C; Ferrara, F; Izzo, T; Mele, G; Riccardi, C | 1 |
| Creutzig, U; Reinhardt, D; Sander, A; Von Neuhoff, C | 1 |
| de Campos-Nebel, M; Elguero, ME; González-Cid, M | 1 |
| Baer, MR; Barcos, M; Blumenson, L; Ferrone, S; Ford, LA; McElwain, BK; Mortazavi, A; Slack, JL; Stewart, CC; Wetzler, M | 1 |
| Canellas, A; Cervera, J; Espinet, B; Florensa, L; Mallo, M; Pajuelo, JC; Pedro, C; Salido, M; Sanz, MA; Solé, F | 1 |
| Campbell, LJ; Catalano, A; Dawson, MA; Iland, H; Opat, S; Schwarer, A; Somana, K | 1 |
| Dardenne, M; de Witte, T; Fenaux, P; Hayat, M; Jaksic, B; Peetermans, M; Selleslag, D; Strijckmans, P; Suciu, S; Zittoun, R | 1 |
| Andreeff, M; Beran, M; Escudier, S; Estey, E; Kantarjian, H; Koller, C; Kornblau, S; O'Brien, S; Pierce, S; Robertson, L | 1 |
| Belotti, D; Corneo, G; Maffè, PF; Pogliani, EM; Rivolta, GF | 1 |
| Hall, JL; Hamblin, TJ; Myint, H; Ross, FM | 1 |
| Andreeff, M; Beran, M; Estey, EH; Kantarjian, HM; Keating, M; Kornblau, S; O'Brien, S; Pierce, S | 1 |
| Alessandrino, EP; Bernasconi, C; Bernasconi, P; Bonfichi, M; Brusamolino, E; Canevari, A; Castagnola, C; Castelli, G; Lazzarino, M; Pagnucco, G | 1 |
| Mandelli, F; Montefusco, E | 1 |
| Appelbaum, FR; Cassileth, PA; Forman, SJ; Harrington, DH; Head, DR; Kopecky, KJ; Mohamed, A; Paietta, E; Rowe, JM; Slovak, ML; Theil, KS; Willman, CL | 1 |
| Cuneo, A; Liso, V; Mestice, A; Pannunzio, A; Rocchi, M; Specchia, G; Storlazzi, CT; Surace, C | 1 |
| Bernasconi, P; Boni, M; Castoldi, GL; Ciolli, S; Clavio, M; Cox, MC; Cuneo, A; Del Poeta, G; Dini, D; Falzetti, D; Fanin, R; Gobbi, M; Isidori, A; Leoni, F; Liso, V; Malagola, M; Mandelli, F; Martinelli, G; Mecucci, C; Petti, MC; Piccaluga, PP; Rondelli, R; Russo, D; Sessarego, M; Specchia, G; Testoni, N; Torelli, G; Tura, S; Visani, G | 1 |
| Ahmed, T; Feldman, EJ; Kancherla, R; Liu, D; Papageorgio, C; Pozzuoli, M; Seiter, K; Sreekantaiah, C; Weisberger, J; Weiss, M | 1 |
| Aivado, M; Aul, C; Germing, U; Giagounidis, AA; Heinsch, M; Hildebrandt, B | 1 |
| Cuello, MT; Fundia, AF; González-Cid, M; Larripa, I | 1 |
| Bendix, K; Hokland, P; Kjeldsen, E; Kristensen, JS; Meyer, K; Nørgaard, JM; Olesen, G; Olesen, LH; Pedersen, B | 1 |
4 review(s) available for idarubicin and Abnormalities, Autosome
| Article | Year |
|---|---|
How I treat older patients with acute myeloid leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Aberrations; Cytarabine; Decitabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Histone Deacetylase Inhibitors; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Prognosis; Remission Induction; Survival Rate; Transplantation, Homologous | 2018 |
[Treatment of acute and chronic leukemias].
Topics: Acute Disease; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chromosome Aberrations; Combined Modality Therapy; Daunorubicin; Humans; Idarubicin; Karyotyping; Leukemia; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Randomized Controlled Trials as Topic; Transplantation, Autologous; Transplantation, Homologous | 1999 |
The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosome Deletion; Chromosome Inversion; Chromosomes, Human; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hepatomegaly; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prognosis; Remission Induction; Retrospective Studies; Splenomegaly; Survival Analysis; Translocation, Genetic; Treatment Outcome | 2001 |
Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 11; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytarabine; Disease Progression; Disease-Free Survival; Enzyme Inhibitors; Etoposide; Female; Humans; Idarubicin; Incidence; Karyotyping; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Neoplasm Proteins; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Topoisomerase II Inhibitors; Treatment Outcome; Tretinoin | 2001 |
9 trial(s) available for idarubicin and Abnormalities, Autosome
| Article | Year |
|---|---|
Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Databases, Factual; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Risk Assessment; Survival Rate; United Kingdom | 2015 |
Phase I study of idarubicin dose escalation for remission induction therapy in acute myeloid leukemia.
Topics: Adult; Antibiotics, Antineoplastic; Biomarkers; Chromosome Aberrations; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Topoisomerase II Inhibitors; Treatment Outcome; Young Adult | 2016 |
Outcome of high-dose cytarabine-based induction therapy followed by hematopoietic stem cell transplantation in acute myeloid leukemia: influence of karyotype.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Survival Rate; Treatment Outcome | 2008 |
Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Chromosome Aberrations; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Combined Modality Therapy; Confidence Intervals; Cytarabine; Cytogenetic Analysis; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Idarubicin; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Male; Probability; Proportional Hazards Models; Radiotherapy, Adjuvant; Reverse Transcriptase Polymerase Chain Reaction; Risk Assessment; Severity of Illness Index; Statistics, Nonparametric; Stem Cell Transplantation; Survival Analysis; Transplantation, Homologous; Treatment Outcome | 2010 |
Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatmen
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chromosome Aberrations; Chromosome Disorders; Cytarabine; Europe; Humans; Idarubicin; Length of Stay; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Pilot Projects; Prognosis; Prospective Studies; Survival Analysis | 1995 |
Treatment of myelodysplastic syndromes with AML-type chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Remission Induction; Vidarabine | 1993 |
Anthracycline drugs and MDR expression in human leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Aberrations; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Prognosis; Remission Induction; Survival Analysis; Treatment Outcome | 1996 |
Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Gene Rearrangement; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Recurrence; Survival Analysis; Treatment Outcome | 1998 |
Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study.
Topics: Acute Disease; Adolescent; Adult; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chromosome Aberrations; Chromosomes, Human; Combined Modality Therapy; Cytarabine; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Remission Induction; Risk; Survival Analysis; Translocation, Genetic; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 2000 |
20 other study(ies) available for idarubicin and Abnormalities, Autosome
| Article | Year |
|---|---|
Core binding factor acute myeloid leukaemia and c-KIT mutations.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosome Aberrations; Core Binding Factors; Cytarabine; Disease-Free Survival; Etoposide; Exons; Female; Humans; Idarubicin; L-Lactate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Prognosis; Proto-Oncogene Proteins c-kit; Retrospective Studies; Stem Cell Transplantation; Young Adult | 2013 |
Identification of clinically important chromosomal aberrations in acute myeloid leukemia by array-based comparative genomic hybridization.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 5; Comparative Genomic Hybridization; Cytarabine; DNA Copy Number Variations; Drug Administration Schedule; Female; Humans; Idarubicin; Kaplan-Meier Estimate; Karyotype; Leukemia, Myeloid; Male; Middle Aged; Outcome Assessment, Health Care; Prognosis; Remission Induction | 2014 |
Prognostic factor analysis in core-binding factor-positive acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factors; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Prognosis; Translocation, Genetic; Treatment Outcome; Young Adult | 2014 |
Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Aberrations; Cytarabine; Decitabine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Recurrence; Remission Induction; Treatment Outcome | 2016 |
Association between the TP53 Arg72Pro polymorphism and clinical outcomes in acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Daunorubicin; Etoposide; Female; Gene Expression; Genetic Predisposition to Disease; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Retrospective Studies; Survival Analysis; Thioguanine; Tumor Suppressor Protein p53 | 2017 |
Chromosomal aberration and micronucleus studies of two topoisomerase (II) targeting anthracyclines.
Topics: Antibiotics, Antineoplastic; Cells, Cultured; Chromosome Aberrations; Doxorubicin; Humans; Idarubicin; Lymphocytes; Micronuclei, Chromosome-Defective; Micronucleus Tests; Mutagens; Topoisomerase II Inhibitors | 2009 |
Rapid response to induction in a case of acute promyelocytic leukemia with MYC amplification on double minutes at diagnosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Female; Gene Amplification; Genes, myc; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Middle Aged; Remission Induction; Time Factors; Tretinoin | 2010 |
Systemic mastocytosis associated with acute myeloid leukaemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Cells; Chromosome Aberrations; Cytarabine; Cytogenetic Analysis; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mast Cells; Mastocytosis, Systemic | 2010 |
Day 15 bone marrow driven double induction in young adult patients with acute myeloid leukemia: feasibility, toxicity, and therapeutic results.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Chromosome Aberrations; Cytarabine; Disease-Free Survival; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Remission Induction; Retrospective Studies; Survival Rate; Time Factors; Transplantation, Homologous; Vidarabine; Young Adult | 2010 |
[Genetic prognostic factors in childhood acute myeloid leukemia].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Chromosome Aberrations; Chromosome Deletion; Chromosome Disorders; Chromosomes, Human, Pair 7; Cytarabine; DNA Mutational Analysis; Etoposide; Female; fms-Like Tyrosine Kinase 3; Genes, Wilms Tumor; Genetic Markers; Humans; Idarubicin; Infant; Kaplan-Meier Estimate; Karyotyping; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Nuclear Proteins; Nucleophosmin; Prognosis; Survival Rate; Translocation, Genetic | 2012 |
DNA-PKcs-dependent NHEJ pathway supports the progression of topoisomerase II poison-induced chromosome aberrant cells.
Topics: Animals; Cell Cycle; Cell Line; CHO Cells; Chromosome Aberrations; Cricetinae; Cricetulus; DNA Breaks, Double-Stranded; DNA Topoisomerases, Type II; Etoposide; G1 Phase; G2 Phase; Idarubicin; Micronuclei, Chromosome-Defective | 2012 |
HLA-DR antigen-negative acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Disease-Free Survival; Female; Flow Cytometry; HLA-DR Antigens; Humans; Idarubicin; Immunophenotyping; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Neoplastic Stem Cells; Prospective Studies; Recurrence; Treatment Outcome | 2003 |
Could ATRA/Idarubicin treatment of acute promyelocytic leukemia induce the appearance of new clonal cytogenetic abnormalities in patients in complete remission?
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Chromosome Aberrations; Chromosomes, Human, Pair 20; DNA, Neoplasm; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Remission Induction; Survival Rate; Translocation, Genetic; Tretinoin | 2007 |
The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Australia; Base Sequence; Bone Marrow; Chromosome Aberrations; Clinical Trials as Topic; Cyclic AMP-Dependent Protein Kinase RIalpha Subunit; DNA Mutational Analysis; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Mutant Chimeric Proteins; Neoplasm Proteins; Oxides; Receptors, Retinoic Acid; Registries; Remission Induction; Retinoic Acid Receptor alpha; RNA, Messenger; Sequence Deletion; Tretinoin | 2007 |
Early transformation to acute myeloblastic leukaemia with the acquisition of inv(16) in Ph positive chronic granulocytic leukaemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosome Disorders; Chromosome Inversion; Chromosome Mapping; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Cytarabine; Fatal Outcome; Humans; Idarubicin; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Philadelphia Chromosome | 1997 |
High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
Topics: Adult; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Chromosome Aberrations; Chromosome Disorders; Confidence Intervals; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Environment, Controlled; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Middle Aged; Platelet Count; Probability; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Vidarabine | 1995 |
Acute promyelocytic leukemia with additional chromosome abnormalities in a renal transplant case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 22; Cytarabine; Humans; Idarubicin; Immunosuppressive Agents; In Situ Hybridization, Fluorescence; Kidney Transplantation; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mitoxantrone; Polycystic Kidney Diseases; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin | 2001 |
Acute basophilic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosome Aberrations; Coloring Agents; Cytarabine; Cytoplasmic Granules; Fatal Outcome; Humans; Idarubicin; Immunophenotyping; Karyotyping; Leukemia, Basophilic, Acute; Leukocyte Count; Male; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Periodic Acid-Schiff Reaction; Peroxidase; Recurrence; Tolonium Chloride; Translocation, Genetic | 2001 |
Correlation between chromosome damage and apoptosis induced by fludarabine and idarubicin in normal human lymphocytes.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Cells, Cultured; Chromosome Aberrations; DNA Fragmentation; Dose-Response Relationship, Drug; Fluorescent Dyes; Humans; Idarubicin; Lymphocytes; Mutagens; Vidarabine | 2002 |
FAB M4 and high CD14 surface expression is associated with high cellular resistance to Ara-C and daunorubicin: implications for clinical outcome in acute myeloid leukaemia.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cohort Studies; Cytarabine; Daunorubicin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Leukemia, Myelomonocytic, Acute; Lipopolysaccharide Receptors; Male; Middle Aged; Mitoxantrone; Multivariate Analysis; Neoplastic Stem Cells; Thioguanine; Treatment Outcome | 2001 |